Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

Key facts

Sponsor

National Institute of Mental Health (NIMH)

Principal Investigator

Judith L Rapoport, M.D.

National Institute of Mental Health (NIMH)

Intervention

Intranasal Oxytocin(drug)

Enrollment

18 enrolled

Eligibility

10-99 years · All sexes

Timeline

2012

Study locations (1)

• National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Childhood-onset schizophrenia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05340348
  Patientheque in Patients With a Psychosis .
  University Hospital, Brest
• ACTIVE NOT RECRUITINGNCT00001246
  Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
  National Institute of Mental Health (NIMH)

See all trials for Childhood-onset schizophrenia →